RS51081B - Nova sinergistička kombinacija koja uključuje roflumilast i formoterol - Google Patents

Nova sinergistička kombinacija koja uključuje roflumilast i formoterol

Info

Publication number
RS51081B
RS51081B YUP-2005/0382A YUP20050382A RS51081B RS 51081 B RS51081 B RS 51081B YU P20050382 A YUP20050382 A YU P20050382A RS 51081 B RS51081 B RS 51081B
Authority
RS
Serbia
Prior art keywords
formoterol
roflumilast
administered
acceptable salt
pharmacologically acceptable
Prior art date
Application number
YUP-2005/0382A
Other languages
English (en)
Serbian (sr)
Inventor
Degenhard Dr. Marx
Norbert dr. KOLASSA
Christian Dr. Weimar
Daniela Dr. Bundschuh
Rolf Dr. Beume
Original Assignee
Nycomed Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh. filed Critical Nycomed Gmbh.
Priority to MEP-2008-782A priority Critical patent/ME00489B/me
Publication of RS20050382A publication Critical patent/RS20050382A/sr
Publication of RS51081B publication Critical patent/RS51081B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
YUP-2005/0382A 2002-11-27 2003-11-26 Nova sinergistička kombinacija koja uključuje roflumilast i formoterol RS51081B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-2008-782A ME00489B (me) 2002-11-27 2003-11-26 NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
PCT/EP2003/013275 WO2004047829A1 (en) 2002-11-27 2003-11-26 New synergistic combination comprising roflumilast and formoterol

Publications (2)

Publication Number Publication Date
RS20050382A RS20050382A (sr) 2007-08-03
RS51081B true RS51081B (sr) 2010-10-31

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0382A RS51081B (sr) 2002-11-27 2003-11-26 Nova sinergistička kombinacija koja uključuje roflumilast i formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (https=)
EP (1) EP1567139B1 (https=)
JP (1) JP2006508994A (https=)
KR (1) KR101071798B1 (https=)
CN (1) CN100346777C (https=)
AT (1) ATE399543T1 (https=)
AU (1) AU2003292120B2 (https=)
BR (1) BR0316451A (https=)
CA (1) CA2506962C (https=)
CO (1) CO5690570A2 (https=)
CY (1) CY1110369T1 (https=)
DE (1) DE60321953D1 (https=)
DK (1) DK1567139T3 (https=)
EA (1) EA009935B1 (https=)
ES (1) ES2309357T3 (https=)
HR (1) HRP20050579B1 (https=)
IL (1) IL168308A (https=)
IS (1) IS2575B (https=)
MA (1) MA27539A1 (https=)
ME (1) ME00489B (https=)
MX (1) MXPA05005437A (https=)
NO (1) NO334247B1 (https=)
NZ (1) NZ540659A (https=)
PL (1) PL216752B1 (https=)
PT (1) PT1567139E (https=)
RS (1) RS51081B (https=)
SI (1) SI1567139T1 (https=)
TN (1) TNSN05131A1 (https=)
UA (1) UA83018C2 (https=)
WO (1) WO2004047829A1 (https=)
ZA (1) ZA200503308B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
ES2443342T3 (es) * 2006-07-05 2014-02-19 Takeda Gmbh Combinación de inhibidor de la HMG-CoA reductasa rosuvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast, roflumilast-N-óxido para el tratamiento de enfermedades pulmonares inflamatorias
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
HUE052275T2 (hu) * 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
AU734122B2 (en) * 1997-02-17 2001-06-07 Takeda Gmbh Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
ES2302350T3 (es) * 1997-02-28 2008-07-01 Nycomed Gmbh Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa.
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2296923T3 (es) * 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
KR100831534B1 (ko) * 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체

Also Published As

Publication number Publication date
TNSN05131A1 (en) 2007-05-14
WO2004047829A1 (en) 2004-06-10
BR0316451A (pt) 2005-10-11
CO5690570A2 (es) 2006-10-31
CY1110369T1 (el) 2015-04-29
WO2004047829A8 (en) 2005-06-30
NO334247B1 (no) 2014-01-20
ES2309357T3 (es) 2008-12-16
MXPA05005437A (es) 2005-08-03
HK1081861A1 (en) 2006-05-26
IS7898A (is) 2005-06-20
CN100346777C (zh) 2007-11-07
ATE399543T1 (de) 2008-07-15
NZ540659A (en) 2007-05-31
CA2506962A1 (en) 2004-06-10
KR20050085104A (ko) 2005-08-29
PL377732A1 (pl) 2006-02-06
EP1567139B1 (en) 2008-07-02
AU2003292120A1 (en) 2004-06-18
RS20050382A (sr) 2007-08-03
ZA200503308B (en) 2006-11-29
AU2003292120B2 (en) 2010-01-21
DK1567139T3 (da) 2008-11-03
NO20052999L (no) 2005-06-17
CA2506962C (en) 2012-01-03
CN1713903A (zh) 2005-12-28
JP2006508994A (ja) 2006-03-16
PL216752B1 (pl) 2014-05-30
EP1567139A1 (en) 2005-08-31
HRP20050579A2 (hr) 2006-04-30
HRP20050579B1 (hr) 2014-01-31
MA27539A1 (fr) 2005-09-01
PT1567139E (pt) 2008-10-01
IS2575B (is) 2010-02-15
EA009935B1 (ru) 2008-04-28
US20060142308A1 (en) 2006-06-29
KR101071798B1 (ko) 2011-10-11
DE60321953D1 (de) 2008-08-14
UA83018C2 (uk) 2008-06-10
EA200500774A1 (ru) 2005-12-29
SI1567139T1 (sl) 2008-12-31
ME00489B (me) 2011-10-10
IL168308A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US6455524B1 (en) Medicament compositions based on anticholinergically-effective compounds and beta-mimetics
PL200923B1 (pl) Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CA2550841C (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
KR20050104367A (ko) 타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물
SK285884B6 (sk) Kombinovaný prípravok formoterolu a tiotrópiovej soli, jeho použitie a farmaceutická súprava, ktoráho obsahuje
CA2588042A1 (en) Compositions and methods for pulmonary conditions
RS51081B (sr) Nova sinergistička kombinacija koja uključuje roflumilast i formoterol
RS51082B (sr) Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol